跳至主要内容
临床试验/ITMCTR2200006153
ITMCTR2200006153尚未招募1 期

A randomized, Controlled, Multicenter Clinical Study Comparing the Efficacy and Safety of Saubude-9 pills in the treatment of Sa disease (cerebral infarction)

Inner Mongolia International Mongolian Medical Hospital0 个研究点开始时间: 待定最近更新:
适应症

试验速览

阶段
1 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Treatment study

入排标准

年龄范围
40 至 75(—)
性别
All

入选标准

  • ? Meet the diagnostic criteria of Western medicine for cerebral infarction in the convalescent period;
  • ? The disease was in line with the diagnostic criteria for anterior circulation cerebral infarction;
  • ? Meet the diagnostic criteria of Mongolian medical Sa disease;
  • ? The course of the disease: 15 to 45 days from the date of onset;
  • ? The first onset, or those with a history of cerebral infarction but no disability before this onset (modified Rankin scale score =1 point);
  • ? Using the National Institutes of Health Observatory Stroke Scale (NIHSS) scoring standard, the score of neurological deficit was =7 points and =22 points;
  • ? Age =40 years old, =75 years old;
  • ? Volunteer subjects and signed informed consent.

排除标准

  • ?Posterior circulation cerebral infarction, lacunar infarction, transient ischemic attack (TIA);
  • ?Those who have suffered from cerebrovascular disease in the past and have severe motor dysfunction;
  • ?Complications affecting drug evaluation, including depression after stroke, dementia, cerebral haemorrhage after cerebral infarction, etc.;
  • ?Stroke patients confirmed by examination to be caused by a brain tumour, brain trauma, blood disease, etc.;
  • ?Patients with cerebral embolism due to rheumatic heart disease, coronary heart disease and other heart disease combined with atrial fibrillation;
  • ?Combined with severe disorders such as liver, kidney, hematopoietic system, endocrine system, osteoarthropathy, mental illness, ALT, AST = 2 times the upper limit of normal, Cr > upper limit of normal;
  • ?Those with a tendency to bleed or those with severe bleeding within 12 weeks;
  • ?Combined with severe hypertension or diabetes and other diseases, those who cannot control the disease after treatment;
  • ?Lack of clear diagnostic evidence such as imaging or insufficient imaging diagnostic evidence to determine the diagnosis;
  • ?Severe illness or coma affects the evaluation of curative effect;
  • ?Those with other diseases that affect the function of limb movement and those with limb movement dysfunction caused by osteoarthritis, rheumatoid arthritis, gouty arthritis, etc., which may affect the nerve or function examination before treatment;
  • ?Those who were unable to independently complete daily activities due to various diseases and constitutions before the disease had a severe impact on the efficacy evaluation;
  • ?Women who are pregnant or planning to become pregnant or breastfeeding;
  • ?Those who are known to be allergic to the ingredients of this drug or have a severe allergic constitution;
  • ?Those who have participated in clinical trials of other drugs within 3 months;
  • ?Those who have used drugs known to major damage organs within 4 weeks;
  • ?dysphagia who cannot take medicine; patients who have undergone thrombolytic therapy;

研究者

发起方
Inner Mongolia International Mongolian Medical Hospital

相似试验